<?xml version="1.0" encoding="UTF-8"?>
<p>The trend toward the hybrid application could indicate that, for certain NBCD product classes, regulatory authorities in EU member states tried to address the uncertainty of the performance of the follow-on candidate products in practice requesting additional (pre)-clinical data using the hybrid application procedure—as done with the marketing approval of Sucrofer®–through decentralized procedure, by the UK authority, in June 2018.</p>
